Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>Toujeo® versus insulin degludec 100 units/mL in T2DM</h3>
 
 BRIGHT - randomised, active-controlled, open-label study6,17

TYPE-2-DIABETES

DIABETES

DOWNLOAD A COMPREHENSIVE SUMMARY OF THE BRIGHT STUDY &gt;

Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T2DM

In this 7-minute video Dr. Alice Cheng tells you about the BRIGHT study, the head-to-head trial comparing Toujeo® vs insulin degludec 100 units/mL meeting the primary endpoint. She tells about the results and why they are relevant and important to her clinical practices, in helping the right patients on the right treatment.​

This slide deck can be used to support Health Care Professional training on Toujeo. It provides clinical evidence of Toujeo in vulnerable patients.​

This slide deck can be used to support Health Care Professional training on Toujeo. It provides an overview of clinical studies including the Bright Study.​

Safety Profile

Abbreviations

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Lantus® (insulin glargine 100 units/mL) Prescribing Information GB

Lantus® (insulin glargine 100 units/mL) Prescribing Information NI

Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

<h3>Toujeo® versus insulin glargine 100 units/mL in T2DM</h3>
EDITION 1, EDITION 2 and EDITION 3 - meta-analysis2,3,12-14 
All individual trials met their primary endpoints: non-inferiority to insulin glargine 100 units/mL in&nbsp;HbA1c&nbsp;&nbsp;reduction from baseline to 6 month12-14

DOWNLOAD A COMPREHENSIVE SUMMARY OF THIS T2DM META-ANALYSIS

<table border="1" cellpadding="1" cellspacing="1">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Lantus® (insulin glargine 100 units/mL) Prescribing Information UK

Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T2DM

<h3>Toujeo® versus insulin degludec 100 units/mL in T1DM</h3>
InRange - randomised, active-controlled, open-label study4,5&nbsp;
Primary endpoint was met: non-inferiority to insullin degludec 100 units/mL for time in range (TIR)&nbsp;≥70 to ≤180 mg/dL (≥3.9 to ≤10 mmol/L) at Week 125

TYPE-1-DIABETES

DOWNLOAD A COMPREHENSIVE SUMMARY OF THE INRANGE STUDY &gt;

Toujeo (insulin glargine 300 Units/mL) Versus insulin degludec 100 units/mL in T1DM

Professor Richard Bergenstal presents the results of the InRange study. This study is the first randomised controlled trial to compare second generation basal insulin analogues Toujeo® and insulin degludec 100 U/mL. It compares adults with T1DM using Time-In-Range (TIR) as the primary endpoint. Watch and learn about the study design and key findings

View the guide to find out more about the impact of time in range on your patients

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a>
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a>
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<h3>Toujeo®&nbsp; versus insulin glargine 100 units/mL in T1DM</h3>
EDITION 4, EDITION JUNIOR and EDITION JP1 - meta-analysis1,8-10&nbsp; &nbsp; &nbsp; &nbsp; 
All individual trials met their primary endpoints: change in HbA1c from baseline to Week 268-10

DOWNLOAD A COMPREHENSIVE SUMMARY OF THIS T1DM META-ANALYSIS

Clinical summary to read about the benefits of Toujeo&reg; in children and adolescents from the age of 6 years in this randomised trial

This slide deck can be used to support Health Care Professional training on Toujeo. It provides an overview of clinical studies T1 Edition Junior and Meta-Analysis

<table border="1" cellpadding="1" cellspacing="1">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Toujeo (insulin glargine 300 Units/mL) Versus insulin glargine 100 units/mL in T1DM

<h4>Would you like to discuss anything about our products with your Haemato-oncology sales specialist? Or want support in ordering Oncology patient materials?</h4>
Leave your request and contact details and we'll get back to you shortly.
For all product-related medical enquiries, please contact Medical Information via&nbsp;<a href="http://www.sanofi.co.uk/en/about-us/sanofi-in-the-uk/contact-us" target="_blank">this link</a>&nbsp;or call +44 (0) 800 035 2525 (Monday - Friday, 08:30 - 17:30, excluding public holidays).

OTHER-ONCOLOGY-TOPICS

ONCOLOGY

Get in Touch with the Haemato-oncology Team

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼&nbsp;(isatuximab) can be found via the Product Card at the bottom of the page.

<table border="1" cellpadding="1" cellspacing="1" style="width: 100%;">
 <tbody>
 <tr>
 <td>
 <h3>Multiple myeloma is a blood cancer accounting for 2% of cancers in the United Kingdom.1</h3>
 Despite available treatments, multiple myeloma remains an incurable malignancy and is associated with significant patient burden, with patients relapsing over time.2&nbsp;As they relapse, patients can become refractory/resistant to treatments.3</td>
 </tr>
 </tbody>
</table>
<table border="1" cellpadding="1" cellspacing="1" style="width: 100%;">
 <tbody>
 <tr>
 <td>
 <h3>Sanofi Oncology is committed to the management of patients with multiple myeloma.</h3>
 SARCLISA®&nbsp;(isatuximab) is indicated:
 In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.
 In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.4</td>
 </tr>
 </tbody>
</table>

<h2>Relapsed Refractory Multiple Myeloma Product</h2>

<a href="http://pro.campus.sanofi/uk/products/sarclisa">Learn more&nbsp; →</a>

<a href="https://pro.campus.sanofi/dam/jcr:6de3a21b-b60e-4a56-afea-e43468d285d6/Sarclisa%20PI%20GB%20May%202024_campus.pdf">Prescribing information GB</a>

MAT-XU-2202578 (v4.0) 
 Date of preparation: June 2024
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

SARCLISA®▼ (isatuximab) Prescribing Information GB

MULTIPLE-MYELOMA

About Multiple Myeloma

Overview of the safety and efficacy data from ICARIA-MM Trial

In this video, you'll learn about
The phase 3 ICARIA-MM study of an anti-CD38 monoclonal antibody triplet regimen in relapsed and refractory multiple myeloma(RRMM) presented by Dr Ramasamy.
SARCLISA®&nbsp;+ Pd demonstrated a 40% risk reduction in progression or death vs Pd (11.53 vs 6.47 months [absolute change 5 months]; HR 0.596, 95% CI: 0.44, 0.81; p=0.001).1

Find out more about SARCLISA&reg;&nbsp;+ Pd efficacy and safety data and dosing information.

Download a handy guide to SARCLISA dosing and administration information

Download SARCLISA&reg;&nbsp;patient information.

Get in touch with the Oncology Team

Independent UK Real World Data.
Data from 107 patients from 24 centres across the UK.

In this video, you'll learn about
An independent UK real world study presented by Professor Basu and Dr Ramasamy. This data was generated across 24 centres including 107 patients, and demonstrated that SARCLISA®&nbsp;+ Pd is effective and achievable in routine clinical care with outcomes comparable to those seen in the phase 3 ICARIA-MM trial.1,2

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
Prescribing Information for SARCLISA®▼(isatuximab) can be found via the Product Card at the bottom of the page.

A Real World Case Study :
Presented by Dr Jane Clark

In this video, you'll learn about
A case study presented by Dr Clark of a 72 year old RRMM patient who rapidly progressed through 3 lines of treatment in 5 years and experienced severe bone disease complications. The patient had concerns about 4th line treatment however received SARCLISA®+ Pd at 4th Line.

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles